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ABSTRACT 
Evidence suggest that both motor and non-motor symptoms contribute to health status (HS) in 
Parkinson’s disease (PD). Less clear is how much change in HS can be expected if these 
clinical variables change.  In addition, anxiety, separate from depression, has rarely been 
examined as a predictor of HS. We used hierarchical multiple regression analysis and 
standardized beta coefficients in a prevalent cohort of 462 patients with Parkinson’s disease to 
explore the relative impact on health status (measured using the Parkinson’s Disease 
Questionnaire) of 5 well-recognized symptom domains in Parkinson’s disease: motor signs, 
depression, anxiety, cognition, and other nonmotor symptoms. In the health status scores, 
19.6% of variance was explained by age, number of comorbidities, disease duration, and 
levodopa equivalent dose. Younger age predicted worse health status. A full regression model 
containing baseline variables and all 5 symptom domains explained 56% of the variance in 
health status. The standardized beta coefficient for depression was 2.1, 1.6, and 1.3 times that 
of motor signs, anxiety, and other nonmotor symptoms, respectively. Our findings provide a 
ranking order of clinical variables for their relative impact on health status in Parkinson’s 
disease and show that depression has more than twice the impact of motor signs on health 
status. Anxiety and other nonmotor symptoms are also important separate determinants of 
poor health status in Parkinson’s disease. Our results will help to guide the development of 
individual care and service planning for patients with Parkinson’s disease. 
 
 
Keywords: relative contribution, Parkinson’s disease, health status, quality of life, non-motor 
symptoms, depression, anxiety
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INTRODUCTION 
In Parkinson’s disease (PD), the primary means of improving health status (HS) has been 
through the better management of motor symptoms, but there is now evidence that non-motor 
symptoms also contribute to HS.1-7 What remains less clear is the relative contribution of 
these clinical characteristics to HS; that is, what relative change can be expected to occur in 
HS when these factors change. This information is important in optimizing an individual 
patient’s management, in understanding how changes in these factors influences the HS of a 
population of PD patients, and in facilitating decision-making regarding health resources in 
the management of PD. 
 
Previous research has often been limited by sample size and inclusion of a limited number of 
possible predictors of HS making interpretation difficult. The relationship between depression 
and HS has been repeatedly demonstrated, but the role of anxiety, separate from depression, is 
not yet clearly understood. Also, physical co-morbidity has largely been ignored.8 The current 
availability of several validated clinical measures 9 means that examination of the role of the 
broader range of non-motor symptoms (NMS) is now possible. Our study used validated 
measures in a large sample to systematically assess which clinical factors contribute to HS.  
 
Our unique aim was to quantify the relative change in HS associated with change in the 
clinical variables. This extends previous studies by ranking the order of the motor and non-
motor variables, and relatively quantifying their impact on HS. Based on existing literature,3, 
6, 8, 10
 we hypothesized that motor symptom severity, depression, anxiety, cognition and non-
motor symptoms would all contribute to HS, that mood and non-motor symptoms would be 
the strongest predictors of HS and changes in mood would have a larger effect on change in 
HS than changes in the other clinical variables. The term HS will be used to refer to impact on 
health.11 
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METHODS 
Patients with PD were recruited consecutively via neurology and care of the elderly clinics in 
the UK as part of a prospective study of mood (PROMS-PD).12 Patients with a diagnosis of 
idiopathic PD according to UK Parkinson’s Disease Society Brain Bank clinical diagnostic 
criteria were eligible for inclusion. Patients with another neurological diagnosis inconsistent 
with a clinical diagnosis of idiopathic PD, severe hearing or visual loss or communication 
difficulties that would interfere with assessments were excluded. Cognitive impairment was 
not a specific exclusion criterion. After providing consent, all patients were assessed in their 
homes. The study was assessed and approved by the South East NHS Research Ethics 
Committee (Ref. 07/MRE01/9). 
 
Assessments 
Assessments used standard published measures developed for or validated for use in PD. 
Information was collected from the patient and/or informant on clinical history and socio-
demographics. Levo-dopa equivalent daily dose (LEDD) was calculated using conversion 
factors described previously.13 Stage of disease was determined using the Hoehn and Yahr 
scale (H&Y).14 Number of co-morbid physical conditions was assessed using the Physical 
Health measure from the Duke Older Americans Resources and Services assessment.15 Motor 
symptoms were assessed using part III of the Unified Parkinson’s Disease Rating Scale 
(UPDRS).16 Patients were rated ‘on’ where possible for practical reasons. The Addenbrooke’s 
Cognitive Exam-Revised (ACE-R)17, validated for use in PD, was used to assess cognition, 
with a total score of less than 84 indicating significant cognitive impairment.18 The Hospital 
Anxiety and Depression Scale (HADS),19 validated for use in PD,20 was used to assess 
depression and anxiety symptoms. A subscale score greater than 10 indicates clinically 
significant depressive or anxiety symptoms while a score of 8-10 indicates possible 
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symptoms. We used the Non-Motor Symptom Scale (NMSS), developed and validated for use 
in patients with PD,9 as a global measure of overall non-motor symptomatology based on 
severity and impact. To avoid overlap of the NMSS score with mood and cognition measures, 
we calculated a score for other NMS (ONMS) by excluding mood and cognition items from 
the NMSS (questions 7-12 and 16-18). HS was assessed using the Parkinson’s Disease 
Questionnaire (PDQ-8), developed and validated in patients with PD and commonly used in 
both research and clinical practice.21-23 It generates a single index score and produces results 
comparable to those gained from the larger PDQ-39.  
 
Statistics and Analysis 
Demographic and disease-related characteristics were summarised with descriptive statistics 
and independent sample t-tests were used for comparison between groups. Clinical and 
demographic factors likely to impact HS (gender, age, disease duration, living alone, LEDD 
and number of physical comorbidities) were entered as independent variables into a baseline 
regression model using PDQ-8 as the dependent variable. Next, each of five symptom 
domains [motor symptom severity (UPDRS-III), depression (HADS-D), anxiety (HADS-A), 
cognition (ACE-R) and other non-motor symptoms (ONMS)] was added individually to the 
baseline model to assess their potential impact on HS. All symptom domains were measured 
on continuous scales. The Kolmogorov–Smirnov test showed that not all data were normally 
distributed, so Spearman’s correlations were used to test for multicollinearity. All variables 
shown to be associated with HS in their own models were then entered together into a full 
regression model. The unique variance explained by each variable was determined by 
subtracting the variable in question from the full model. The relative impact of each symptom 
domain on HS was determined by using standardised regression coefficients. These 
coefficients were standardised to measure the impact on HS of minimally important change 
(MIC) on the measurement tools (where known).   
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RESULTS 
462 patients completed all assessments and were included in the analysis. Their characteristics 
are shown in Table 1. Possible and definite depression were present in 21.2% and 11.9% 
respectively, and these patients combined had significantly worse HS than those who were not 
depressed. Almost one-quarter (23.6%) of patients were on an anti-depressant at time of 
assessment. 
 
A baseline regression model accounted for 19.6% of variance in PDQ-8 scores with worse HS 
predicted by a younger age, greater number of physical co-morbidities, living alone, longer 
disease duration and higher LEDD.  
 
Each symptom domain contributed a significant amount of variance when entered 
independently after the baseline measures: depression (26.7% additional variance), anxiety 
(19.0%), non-mood and non-cognitive NMS (17.7%), motor symptom severity (9.0%) and 
cognition (2.5%). As each symptom domain significantly predicted HS in their individual 
regression models and there was no evidence of multicolliniarity (all intercorrelations less 
than 0.6)24 all planned variables were included in the full regression model. 
 
The full model (Table 2) explained 56.2% of the variance in HS, an increase of 36.6% from 
the baseline model. The unique variance explained by each variable is shown in Table 3; 
depression explained the largest portion of variance, and more than ONMS, anxiety and motor 
state. The unique variance contributions obtained from the full model were smaller than those 
obtained from the individual regression models owing to the fact that domain scores were 
positively correlated. In the final model (adjusting for other domain effects), cognition was no 
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longer significantly associated with HS but the effects of the other four domains remained 
significant (Table 2).  
 
The adjusted standardized beta coefficient (Table 2) obtained from the full model for HADS-
D was 2.1, 1.6 and 1.3 times that of UPDRS III, HADS-A and ONMS respectively.  
 
DISCUSSION 
The strengths of our study lie in its large sample, use of validated measures and use of an a 
priori specified hierarchical regression approach according to suggested best practice 
methods.24  Analysis is based on predetermined hypotheses and is less likely to generate 
spurious results than automated variable selection methods. Although the removal of the 
mood and cognition components of the total NMSS means that our measure of “other NMS” 
is not a truly validated scale, the step was necessary to minimize overlap between the different 
measures and is analogous to motor studies using subsections of the UPDRS. We used the 
concept of MIC to interpret our data in a clinically relevant way. There is growing consensus 
regarding the clinically important effect size, and we used a half standard deviation, as 
suggested by Sloan et al.25 
 
Our study has demonstrated the degree to which symptom domains in PD contribute to HS 
and provide a unique relative ranking of common domains affecting HS. We quantified this 
by showing that depression has more than twice the impact on HS than motor state and 1.6 
times the impact of anxiety, that is, a half SD of change in depression (measured by HADSD) 
would lead to 2.1 times the impact on HS, compared with a half SD of change of motor state 
(measured by ‘‘on’’ UPDRS-III). These data can be clinically interpreted for UPDRS-III and 
HADS. The minimal change in UPDRS-III considered clinically important ranges from 2.3 to 
5 points,26,27 so the value for 0.5 SD of change in our data (5.8 points) would be considered 
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clinically meaningful. In terms of absolute numbers, available data on minimally important 
changes for HADS-D and HADS-A are sparse. In a population of patients with pulmonary 
disease, the minimal important difference on the HADS was found to be 1.5 points.28 
Therapeutic trials of antidepressants have reported differences in mean HADS scores ranging 
from 2.6 to 4.1 points.29 Specifically in PD, mean differences of 1.7–2.7 points on the HADS 
were also considered meaningful.30 Therefore, the change of 0.5 SD for HADS in our model 
(1.8–2.25 points) would be comparable to these. The degree of change in PDQ-8 affected by 
the magnitude of change in the independent variables confirmed that depression has greater 
than twice the impact of motor score and 1.6 times the impact of anxiety, but to our 
knowledge, no data are available on the minimal clinically important change for the NMSS or 
ACE-R to permit clinical interpretation for other NMSS or cognition. Given the cross-
sectional nature of the study, our data and interpretations are offered as preliminary to raise 
awareness of this concept. Further studies are required before they can be used for clinical 
management or planning of patient care. 
 
Our results extend the study by Schrag et al,6 who used a different set of independent 
variables in a smaller cohort of 92 PD patients. They found depression (Beck Depression 
Inventory (BDI) was most predictive of HS, followed by disability (Schwab and England 
scale), postural instability (UPDRS-III subscore), and cognition (Folstein Mini–Mental State 
Examination). Two other studies, both using automated variable selection methods, are 
noteworthy for their large sample sizes. Qin et al31 studied 391 mild– moderate 
PD patients in the ‘‘off’’ state and, using a variety of scales, found that depression, sleep 
disorders, and fatigue were significant predictors of HS (SF-36), whereas motor severity, 
disease stage, and LEDD did not make an independent contribution. The Global PD Survey 
Steering Committee32 studied 902 PD patients and found that depression, H&Y stage, and 
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medication were significant predictors of HS (PDQ- 39) and explained a total of 59.7% of 
variance in HS. 
 
However, a more limited number of variables were assessed than in our study. Numerous 
smaller studies have reported a contribution to HS from depression,3– 5,8,33–36 anxiety,8,34,35 
axial motor impairment,8 shuffling gait,35 bradykinesia,8 motor symptom severity,37 difficulty 
turning in bed,35 cognition,2,4,6 LEDD,4,8,33 duration of L-dopa treatment,4 disability,33–35 
disease severity,5,36 age,5 clinical fluctuations,36,37 comorbidities, 8 and sleep problems.3 
Although the contribution of depression to HS is a consistent finding, a relative ranking of 
symptoms in terms of quantitative impact on HS is difficult to interpret from these studies. 
 
We found that anxiety is an independent predictor of HS. It also has greater impact on HS 
than motor severity. Rahman et al35 reported greater effects of depression (BDI) than anxiety 
(Beck Anxiety Inventory). In contrast, Muslimovic et al8 found that depression and anxiety 
were related to HS to a similar extent. In a group of Brazilian PD patients, Carod-Artal et al34 
determined that depression and anxiety were correlated with PDQ-39; however, anxiety 
(HADS-A) and depression (HADS-D) were alternately included in multiple regression, so no 
clear conclusion could be drawn about the relative impact of one versus the other on HS. 
Although there is growing interest in the role of anxiety in PD, which is, if anything, more 
common than depression,38 our new results suggest that it may have less impact on HS than 
depression. A previous study using the NMSS demonstrated that the total score was the 
largest single predictor of HS (PDQ-8); r = 0.70.9 However, the NMSS contains items 
relating to depression, anxiety, cognition, and other symptoms, and so it is unclear the extent 
to which the broad range of NMS was contributing to HS rather than these specific measures. 
Our use of a restricted NMS score, eliminating mood and cognition components, 
demonstrated that the full range of other NMS was still highly predictive of HS, emphasizing 
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the importance of symptoms such as gastrointestinal, urinary, sexual, and sleep disturbance 
(although their independent interpretation is not considered in this study). 
 
When considered with other symptoms, cognitive function did not emerge as an important 
predictor of HS, similar to the results of Muslimovic et al.8 Visser et al39 demonstrated that 
PD patients with cognitive dysfunction are at risk for deterioration in quality of life over time, 
although not all studies support an association.5 Klepac et al40 concluded that some of the 
reported association may be mediated by depression, with an association between cognitive 
impairment and HS only in patients with lower depression scores; in patients with higher 
depression scores, HS was poor regardless of cognitive status. 
 
Several other points from our study are noteworthy. Few previous studies have addressed the 
impact of comorbid health conditions on HS in PD,8,34,36 despite that this age group can be 
expected to have numerous other health conditions that could potentially influence HS. We 
found that despite being an independent predictor of HS, number of physical comorbidities 
lost significance when all symptom domains were included in the regression model; some of 
the variance explained by other health conditions may have been captured by symptoms 
measured by the ONMS (eg, pain, sleep disturbance). We found younger age predicted worse 
HS, perhaps reflecting the greater demands and expectations of younger PD patients. 
Our findings are consistent with Schrag et al,41 who showed that moderate–severe depression 
was present in a significantly higher proportion of patients in a young-onset (<50 years) group 
(40%) compared with an old-onset (>50 years) group (17%). 
 
Our study has several limitations. First, our large sample was composed of patients seen in 
specialist clinics and may not extrapolate to community-based samples. Second, the effects of 
normal aging are difficult to separate from the effects of PD without age-matched controls. 
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Third, many factors may contribute to the complex concept of HS, and although we measured 
selected variables hypothesized to contribute, a significant proportion of variance in HS 
remains unexplained. Fourth, as we did not measure the severity of patients’ motor ‘‘off’’-
state symptoms, we cannot comment on their impact. However, as most patients are in an 
‘‘on’’ state most of the time, the severity of symptoms in this state is probably more useful as 
an overall indicator of daily motor performance. Finally, because of the cross-sectional 
design, we were unable to make inferences regarding causality. 
 
In summary, our findings emphasize the importance of focusing outcomes in PD on multiple 
measures of HS. We demonstrate that depression has more than twice the impact of motor 
state on HS. Anxiety, separate from depression, is also important and merits individual 
attention. Other combined nonmotor symptoms influence HS, but individual contributions 
cannot be extrapolated from this study. Cognition alone appears to influence HS but becomes 
less influential when combined with other symptoms; reasons for this are unclear. Younger 
age predicts worse HS, suggesting a need for heightened awareness in this group. Physical 
comorbidities do not independently influence HS. Our results are preliminary, but they 
emphasize the potential importance of screening for and managing depression, anxiety, and 
nonmotor symptoms in PD patients, individually and collectively. With further research, 
particularly longitudinal studies of measurement of change following targeted intervention, 
greater importance and more health resources may need to be attached to the management of 
NMS to improve patient outcome.  
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Table 1 – Patient characteristics (N=462) 
 
Variable Mean (SD) Range 
Demographic and social characteristics   
age (years) 67.5 (10.3) 32-94 
gender (% male) 64.9 - 
ethnicity (% white) 96.3 - 
currently working (% full- or part-time) 13.4 - 
living alone (%) 20.1 - 
Physical health   
number of physical health conditions 
including PD 
2.9 (1.7) 1-11 
PD history and treatment   
age of PD onset (years) 60.6 (11.9) 13-92 
duration of PD since diagnosis (years) 5.0 (8.0) † 0-39 
LEDD (mg/day) 600.0 (720.0)† 0-7365* 
Clinical scales   
UPDRS-III total score 25.9 (11.6) 4-78 
Hoehn & Yahr stages I/II-III/IV-V (%) 12.6/81.4/5.9 - 
Total NMSS score 48.0 (52.3) † 0-235 
ONMS (NMSS minus mood & cognition) 37.3 (35.3) † 0-150 
HADS-depression score 6.1 (3.6) 0-17 
HADS-anxiety score 7.1 (4.5) 0-20 
ACE-R total score 86.9 (10.3) 46-100 
PDQ-8 score 29.5 (18.5) 0-100 
†Interquartile range 
LEDD – levodopa equivalent daily dose; UPDRS-Unified Parkinson’s Disease Rating Scale; 
NMSS – Non-motor Symptoms Scale; ONMS – other non-motor symptoms; HADS – 
Hospital Anxiety and Depression Scale; ACE-R – Addenbrooke’s Cognitive Examination-
Revised; PDQ – Parkinson’s Disease Questionnaire 
*This very high score represents a patient on continuous subcutaneous apomorphine infusion. 
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Table 2. Results of final multiple regression analysis of PDQ-8 scores (final model) 
 
Independent 
variables 
Standardised 
regression 
(beta) 
coefficients 
P-value Regression 
coefficients 
95% CI Adjusted 
R2‡ 
Gender 0.006 0.857 0.073 -0.718 – 0.864  
Age  -0.141 < 0.001* -0.081 -0.124 – -0.039  
Living alone 0.047 0.144 0.684 -0.235 – 1.604  
No. of physical of 
health conditions 
0.055 0.108 0.194 -0.043 – 0.431  
Duration of PD 
(yrs)  
0.096 0.009* 0.095 0.024 – 0.167  
LEDD  0.074 0.039* 0.001 0.000 – 0.001  
ACE-R -0.043 0.224 -0.025 -0.064 – 0.015  
UPDRS-III  0.148 < 0.001* 0.076 0.039 – 0.113  
HADS-A  0.196 < 0.001* 0.259 0.152 – 0.366  
NMSS (minus 
mood & cognition)  
0.232 < 0.001* 0.053 0.036 – 0.069  
HADS-D  0.308 < 0.001* 0.503 0.373 – 0.633  
 
    0.562 
(p<0.001)*  
 
*statistically significant results 
‡ Adjusted R2 = estimated proportion of the variance of PDQ-8 explained by the model 
including all listed independent variables. 
 
Table 3. Results of subtraction from full regression to determine unique variance 
portion of each variable. 
 
Independent 
variables 
Full model 
adjusted R2 
Adjusted R2 with 
variable removed 
Unique % variance 
explained by variable 
Depression 0.573 0.517 5.6% 
NMSS* 0.573 0.536 3.7% 
Anxiety 0.573 0.551 2.2% 
UPDRS 0.573 0.560 1.3% 
ACE-R 0.573 0.571 0.2% 
* NMSS  minus mood and cognition components 
 
